Scholar Rock Holding Corp logo

Scholar Rock Holding Corp

NAS:SRRK (USA)  
$ 13.18 -1.25 (-8.65%) 11:09 PM EST
At Loss
P/B:
4.43
Market Cap:
$ 950.85M
Enterprise V:
$ 887.33M
Volume:
719.71K
Avg Vol (2M):
734.38K
Also Trade In:
Volume:
719.71K
At Loss
Avg Vol (2M):
734.38K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Scholar Rock Holding Corp ( ) from 2018 to Mar 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Scholar Rock Holding stock (SRRK) PE ratio as of Mar 19 2024 is 0. More Details

Scholar Rock Holding Corp (SRRK) PE Ratio (TTM) Chart

To

Scholar Rock Holding Corp (SRRK) PE Ratio (TTM) Historical Data

Total 1252
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Scholar Rock Holding PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-03-19 At Loss 2024-01-11 At Loss
2024-03-15 At Loss 2024-01-10 At Loss
2024-03-14 At Loss 2024-01-09 At Loss
2024-03-13 At Loss 2024-01-08 At Loss
2024-03-12 At Loss 2024-01-05 At Loss
2024-03-11 At Loss 2024-01-04 At Loss
2024-03-08 At Loss 2024-01-03 At Loss
2024-03-07 At Loss 2024-01-02 At Loss
2024-03-06 At Loss 2023-12-29 At Loss
2024-03-05 At Loss 2023-12-28 At Loss
2024-03-04 At Loss 2023-12-27 At Loss
2024-03-01 At Loss 2023-12-26 At Loss
2024-02-29 At Loss 2023-12-22 At Loss
2024-02-28 At Loss 2023-12-21 At Loss
2024-02-27 At Loss 2023-12-20 At Loss
2024-02-26 At Loss 2023-12-19 At Loss
2024-02-23 At Loss 2023-12-18 At Loss
2024-02-22 At Loss 2023-12-15 At Loss
2024-02-21 At Loss 2023-12-14 At Loss
2024-02-20 At Loss 2023-12-13 At Loss
2024-02-16 At Loss 2023-12-12 At Loss
2024-02-15 At Loss 2023-12-11 At Loss
2024-02-14 At Loss 2023-12-08 At Loss
2024-02-13 At Loss 2023-12-07 At Loss
2024-02-12 At Loss 2023-12-06 At Loss
2024-02-09 At Loss 2023-12-05 At Loss
2024-02-08 At Loss 2023-12-04 At Loss
2024-02-07 At Loss 2023-12-01 At Loss
2024-02-06 At Loss 2023-11-30 At Loss
2024-02-05 At Loss 2023-11-29 At Loss
2024-02-02 At Loss 2023-11-28 At Loss
2024-02-01 At Loss 2023-11-27 At Loss
2024-01-31 At Loss 2023-11-24 At Loss
2024-01-30 At Loss 2023-11-22 At Loss
2024-01-29 At Loss 2023-11-21 At Loss
2024-01-26 At Loss 2023-11-20 At Loss
2024-01-25 At Loss 2023-11-17 At Loss
2024-01-24 At Loss 2023-11-16 At Loss
2024-01-23 At Loss 2023-11-15 At Loss
2024-01-22 At Loss 2023-11-14 At Loss
2024-01-19 At Loss 2023-11-13 At Loss
2024-01-18 At Loss 2023-11-10 At Loss
2024-01-17 At Loss 2023-11-09 At Loss
2024-01-16 At Loss 2023-11-08 At Loss
2024-01-12 At Loss 2023-11-07 At Loss

Scholar Rock Holding Corp (SRRK) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company primarily operates in the United States. The company's lead product candidate is Apitegroma which is a highly selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.